Symptom remission at 12-weeks strongly predicts long-term recovery from the first episode of psychosis by Dazzan, Paola et al.
Psychological Medicine
cambridge.org/psm
Original Article
*Joint first author
Cite this article: Dazzan P et al (2019).
Symptom remission at 12-weeks strongly
predicts long-term recovery from the first
episode of psychosis. Psychological Medicine
1–11. https://doi.org/10.1017/
S0033291719001399
Received: 30 November 2018
Revised: 18 April 2019
Accepted: 28 May 2019
Key words:
Clinical outcome; functional outcome;
psychosis; remission; schizophrenia
Author for correspondence:
Paola Dazzan, E-mail: paola.dazzan@kcl.ac.uk
© Cambridge University Press 2019. This is an
Open Access article, distributed under the
terms of the Creative Commons Attribution
licence (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted re-use,
distribution, and reproduction in any medium,
provided the original work is properly cited
Symptom remission at 12-weeks strongly
predicts long-term recovery from the first
episode of psychosis
Paola Dazzan1,2,*, Julia M. Lappin3,*, Margaret Heslin4,2, Kim Donoghue5,
Ben Lomas6, Uli Reininghaus4,7, Adanna Onyejiaka1, Tim Croudace8,
Peter B. Jones9, Robin M. Murray1,2, Paul Fearon10, Gillian A. Doody6
and Craig Morgan4,2
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London,
London, UK; 2National Institute for Health Research Mental Health Biomedical Research Centre at South London
and Maudsley NHS Foundation Trust and King’s College London, London, UK; 3School of Psychiatry, Faculty of
Medicine, University of New South Wales, Sydney, Australia; 4Department of Health Service & Population Research,
Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 5Department of
Addictions, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 6Department
of Psychiatry, University of Nottingham, Nottingham, UK; 7Department of Public Mental Health, Central Institute of
Mental Health, Medical Faculty Mannheim, Heidelberg University; 8School of Nursing & Health Sciences, University
of Dundee, Dundee, UK; 9University of Cambridge, and Cambridgeshire and Peterborough NHS Foundation Trust,
Cambridge, UK and 10Discipline of Psychiatry, School of Medicine, Trinity College, Dublin, Ireland
Abstract
Background. To determine the baseline individual characteristics that predicted symptom
recovery and functional recovery at 10-years following the first episode of psychosis.
Methods. AESOP-10 is a 10-year follow up of an epidemiological, naturalistic population-
based cohort of individuals recruited at the time of their first episode of psychosis in two
areas in the UK (South East London and Nottingham). Detailed information on demographic,
clinical, and social factors was examined to identify which factors predicted symptom and
functional remission and recovery over 10-year follow-up. The study included 557 individuals
with a first episode psychosis. The main study outcomes were symptom recovery and func-
tional recovery at 10-year follow-up.
Results. At 10 years, 46.2% (n = 140 of 303) of patients achieved symptom recovery and 40.9%
(n = 117) achieved functional recovery. The strongest predictor of symptom recovery at 10
years was symptom remission at 12 weeks (adj OR 4.47; CI 2.60–7.67); followed by a diagnosis
of depression with psychotic symptoms (adj OR 2.68; CI 1.02–7.05). Symptom remission at 12
weeks was also a strong predictor of functional recovery at 10 years (adj OR 2.75; CI 1.23–
6.11), together with being from Nottingham study centre (adj OR 3.23; CI 1.25–8.30) and hav-
ing a diagnosis of mania (adj OR 8.17; CI 1.61–41.42).
Conclusions. Symptom remission at 12 weeks is an important predictor of both symptom and
functional recovery at 10 years, with implications for illness management. The concepts of
clinical and functional recovery overlap but should be considered separately.
Introduction
Our ability to predict outcome following a first psychotic episode remains limited. Decades of
research have shown that factors such as earlier age of onset, male gender, longer duration of
untreated illness, and insidious onset are each grossly associated with worse outcome in
schizophrenia (Johnstone et al., 1989; Jablensky et al., 1992; Leung and Chue, 2000;
Marshall et al., 2005; Rabinowitz et al., 2006). None of these factors, however, has proven sen-
sitive or specific enough to be clinically useful in predicting the outcome for an individual.
This lack of knowledge about clinically useful predictors reflects several issues. First, long-
term cohort studies of first-episode psychosis (FEP) to date have evaluated prevalence samples
with schizophrenia only (rather than all psychoses), which tend to have an over-representation
of patients with poorer outcomes and an under-representation of those who do not remain in
treatment (van Os et al., 1997). Second, many have implemented structured treatment proto-
cols, not necessarily reflective of real-life practice, with consequent limited generalizability of
findings. Third, there has been variability in the timeframes evaluated, the assessment tools
used, and the outcome measures reported. Definitions used for remission and recovery, for
example, range from the total absence of symptoms (Thara et al., 1994) to symptoms present
below a certain threshold (Crumlish et al., 2009) for variable periods of time. Finally, symptom
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remission and social functioning have often been reported
together, with both considered necessary for a good outcome,
although such coupling lacks an empirical basis.
Evidence from short-term (up to 2 years) follow-up studies
and clinical trials suggests that early improvement in symptom
severity may predict response to antipsychotic drugs and short-
term clinical outcome (Craig et al., 1999; Robinson et al., 1999;
Emsley et al., 2006). Although symptomatic improvement follow-
ing first treatment (4–6 weeks to 3 months) has been associated
with better outcome at 1–2 years (Lieberman et al., 1993;
Robinson et al., 1999), its relationship with longer-term outcome
remains unclear. Follow-up studies of more than 8 years’ duration
have indirectly reported that non-specific measures of early remis-
sion, such as ‘prompt treatment’ (Friis et al., 2016) and ‘shorter
proportion of time spent experiencing symptoms in first few
years of illness’ (Wiersma et al., 1998; Harrison et al., 2001;
Hegelstad et al., 2012) are associated with better long-term out-
come. None of these studies has evaluated the role of time to
the first remission according to operationalised criteria in long-
term outcome.
In order to move towards a novel framework for targeted inter-
ventions, we need longitudinal data from unselected samples of
incident cases of all psychoses (not just schizophrenia), evaluated
using clear operational definitions of symptomatic and functional
outcomes. Factors that predict sustained symptom remission and
functional recovery should be explored separately to inform dif-
ferential interventions. This is what we aimed to do in this unique
study.
In a large cohort of individuals experiencing FEP, we evaluated
predictors of symptom and functional remission and recovery
over the subsequent 10-years in three domains (demographic,
clinical, social) (Morgan et al., 2014).
Method
We conducted a 10-year follow-up study (ÆSOP-10) of an epi-
demiological cohort of 557 individuals initially assessed at the
time of their first episode of psychosis (FEP) in two UK centres,
south-east London (urban) and Nottingham (semi-urban). This
sample comprised all incident cases who presented to specialist
mental health services within tightly-defined catchment areas in
the two centres (n = 532). The study was approved by the local
Research Ethics Committees.
Our procedures for tracing cases were in line with those of pre-
vious long-term follow-up studies of psychosis (Harrison et al.,
2001; White et al., 2009). At approximately 10-years after inclu-
sion, we sought to trace and re-interview all cases included in
the baseline study (see Morgan et al., 2014).
Baseline
At baseline, information was collated on clinical presentation and
demographic and social characteristics. Assessments were com-
pleted on a range of clinical and social risk factors (Morgan
et al., 2006). Baseline ICD-10 and DSM-IV diagnoses were deter-
mined at consensus meetings using data collected with the
Schedules for Clinical Assessment in Neuropsychiatry (SCAN)
(WHO, 1992). From this schedule, a series of symptom dimen-
sions (mania, reality distortion, negative, depressive and disorgan-
ization) was obtained (Demjaha et al., 2009). We created an index
of disadvantage by counting the presence of four markers: living
alone, being single, being unemployed, living in rented housing.
Symptom course and outcome
We used an extended version of the WHO Life Chart to collate
information across symptom and social course and outcome, as
previously described (Morgan et al., 2014). The Life Chart has
been used successfully in previous long- term follow-up studies,
including those with follow-up periods in excess of 10-years,
and is designed to collate information from multiple sources
(Sartorius et al., 1996; Morgan et al., 2014). We included add-
itional substance use and service contact information, and a time-
line to document psychotic symptoms and contacts with mental
health services. We recorded prescription of, and compliance
with, anti-psychotic medications throughout the follow-up.
Although the Life Chart has been shown to produce reliable rat-
ings (Susser et al., 2000), all clinical ratings were made by
consensus.
Information on symptoms in the month preceding follow-up
was collected using the Schedules for Clinical Assessment in
Neuropsychiatry (SCAN) Version 2 (WHO, 1992), the Scale for
the Assessment of Negative Symptoms (SANS), and the Global
Assessment of Function (symptom score) (Endicott et al.,
1976). Information from the Life Chart and SCAN were used to
make a lifetime diagnosis.
Symptom remission and recovery
In line with Andreasen and colleagues (Andreasen et al., 2005), we
defined remission as absence of overt psychotic symptoms (operatio-
nalised as a score of 2 or 3 onRating Scale 2 in the SCAN; 0 = absence,
1 = symptom occurred, but fleeting, 2 = symptom definitely present,
3 = symptom present more or less continuously) for a period of at
least 6 months. We used the symptom criteria to define early symp-
tomatic remission beginning at most 3 months after the first contact.
We defined symptom recovery as sustained remission for 2 or more
years.
Social functioning and functional recovery
Information on sociodemographic markers of social function and
integration across a number of domains (housing, employment,
relationships, education, and social networks) over follow-up
was collected using the Life Chart (Table 2). Information on
social function in the month prior to follow-up was collected
using the Life Chart and the GAF (disability score) (24). GAF
score equal to or greater than 60 was used to define functional
recovery.
Analysis
We describe primary outcomes using frequencies and percen-
tages, and means or medians and standard deviations or inter-
quartile ranges. We examined associations between each set of
putative baseline and early course predictors and (a) symptom
recovery at 10 years using logistic regression and (b) functional
recovery (i.e. GAF > 60) at 10 years using linear regression. We
first fit univariable models and then adjusted (a) for study centre,
age, gender, and ethnicity and (b) in turn, for other variables
found to be associated with each outcome, retaining in the final
models only those variables that improved model fit based on
likelihood ratio tests. For final models, we further report
pseudo-R2 statistics and percentage recovered correctly predicted,
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estimated using post-estimation commands in Stata. All analyses
were conducted using Stata 13.
Results
Description of the sample
Of the original 532 incident cases, 37 (7.0%) had died, 29 (5.5%)
had left the country and 8 (1.5%) were excluded based on infor-
mation not available at baseline. Of the remaining 458 cases, we
obtained useable information on symptom course and outcome
across one or more of our three domains on 387 (84.5% of
458) for at least 8 years of follow-up. There were no systematic dif-
ferences by age, gender, ethnicity, duration of untreated psychosis
(DUP), baseline employment, baseline diagnosis, mode of initial
contact with mental health services, or study centre between
those with follow up information and those without (Morgan
et al., 2014). The sample characteristics are presented in Table 1.
Remission and symptom and functional recovery at 10 years
Details of illness course and symptom and social outcome have
been previously reported (Morgan et al., 2014). Briefly, at
follow-up 213 cases (65.3% of 326) were not experiencing psych-
otic symptoms and 140 (46.2% of 303 on whom complete data
were available) met criteria for recovery. Relevant to this study,
77 (57.9%) of these had been in remission at 12-weeks, compared
with 34 (22.8% of 163) of those who were not in recovery at
10-years (Table 2). Among cases for whom we had reliable medi-
cation information (228; 75.2% of 303 with data on recovery),
56.4% of those who were recovered (57 of 101) had been pre-
scribed antipsychotic medication in the preceding 2-years, v.
85.8% (109 of 127) of those not recovered (χ2 24.6, df 1, p <
0.001) (Note: all cases were, at some point, prescribed anti-
psychotic medication).
Functional recovery at 10 years (GAF ⩾ 60) was achieved by
117 (40.9% of 286). Only a minority had been in paid work for
over 75% of the follow-up period (34 of 290; 11.7%), and a minor-
ity for between 25% and 75% of the follow-up (48; 16.6%), with
the overwhelming majority employed for <25% (208, 71.7%).
Table 1. Demographic, social, and clinical characteristics of the sample
Total sample (n = 387)
Median (IQR)
Age (years) 29.0 (22.0–36.0)
Duration of untreated psychosis (weeks)a 8.3 (2.0–32.2)
Length of follow-up (years)b 10.7 (9.8–11.4)
No (%)
Study centre
London 230 (59.4)
Nottingham 157 (36.1)
Gender
Male 215 (55.6)
Female 172 (44.4)
Ethnicity
White British 167 (43.2)
Black Caribbean 108 (27.9)
Black African 45 (11.6)
White Other 25 (6.5)
Asian 22 (5.7)
Other (all) 20 (5.2)
Place of birthc
UK 288 (76.0)
Non-UK 91 (24.0)
Lifetime Substance Abuse/Dependenced 77 (22.9)
Lifetime Alcohol Abuse/Dependenced 54 (16.1)
Baseline diagnosis
Schizophrenia 167 (43.2)
Mania 54 (14.0)
Depression 56 (14.5)
Schizoaffective 18 (4.7)
Brief 35 (9.0)
Other 57 (14.7)
Acute mode of onsete 157 (46.0)
Course Typef
No further episodes 43 (12.5)
Episodic 69 (20.0)
Neither 153 (44.3)
Continuous 80 (23.2)
Recovered (symptoms)g 140 (46.2)
Recovered (functional)h 117 (40.9)
Employed at follow-upi 66 (22.8)
Marital status (follow-up)j
Married/steady relationship 95 (31.7)
Single 205 (68.3)
(Continued )
Table 1. (Continued.)
Total sample (n = 387)
Median (IQR)
Parental status (follow-up)k
No children 164 (55.6)
Parent, lives with child 80 (27.1)
Parent, child lives with others 51 (17.3)
IQR, Interquartile range
aMissing, 14.
bMissing, 126.
cMissing, 8.
dMissing, 51.
eMissing, 46.
fMissing, 42.
gMissing, 84.
hMissing, 101.
iMissing, 98.
jMissing, 87.
kMissing, 92.
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Table 2. Symptomatic Recovery at 10 years (unless specified, number included in analyses = 303)
Not recovered (N = 163) N
(%) or mean (S.D.)
Recovered (N = 140)
N (%) or mean (S.D.)
Unadj.
OR 95% CI p
Adj. OR
(1)a 95% CI p
Demographic
Study Centre
London 109 (66.9) 94 (67.1) 1.00 – – 1.00 – –
Nottingham 54 (33.1) 46 (32.9) 0.99 0.61–1.60 0.960 0.63 0.36–1.14 0.128
Sex
Men 95 (58.3) 67 (47.9) 1.00 – – 1.00 – –
Women 68 (41.7) 73 (52.1) 1.52 0.97–2.39 0.070 1.53 0.96–2.43 0.077
Age
16–29 88 (54.0) 74 (52.9) 1.00 – – 1.00 – –
30–64 74 (46.0) 66 (47.1) 1.05 0.67–1.65 0.844 0.97 0.61–1.54 0.881
Ethnicity
White British 53 (32.5) 66 (47.1) 1.00 – – 1.00 – –
Other 110 (67.5) 74 (52.9) 0.54 0.34–0.86 0.010 0.43 0.25–0.76 0.003
Social
Index of social disadvantageb
0, 1 21 (16.4) 37 (31.6) 1.00 – – 1.00 – –
2 31 (24.2) 30 (25.6) 0.55 0.26–1.14 0.110 0.53 0.24–1.18 0.121
3 40 (31.3) 30 (25.6) 0.43 0.21–0.87 0.019 0.40 0.18–0.87 0.021
4 36 (28.1) 20 (17.1) 0.32 0.15–0.68 0.003 0.29 0.13–0.67 0.003
Loss, separation from parentc
None 56 (47.1) 58 (53.2) 1.00 – – 1.00 – –
Loss (parent died) 10 (8.4) 12 (11.0) 1.16 0.46–2.90 0.753 1.07 0.40–2.86 0.889
Separation from
parent
53 (44.5) 39 (35.8) 0.71 0.41–1.24 0.226 0.70 0.39–1.28 0.245
Educationd
University 12 (7.6) 20 (14.5) 1.00 – – 1.00 – –
Further 50 (31.9) 31 (22.5) 0.37 0.16–0.87 0.022 0.48 0.20–1.19 0.114
GCSE 42 (26.8) 42 (30.4) 0.60 0.26–1.38 0.230 0.77 0.32–1.88 0.569
No qualifications 53 (33.8) 45 (32.6) 0.51 0.22–1.16 0.106 0.61 0.25–1.45 0.263
Early symptom course
Remission at 12 weekse
No 115 (77.2) 56 (42.1) 1.00 – – 1.00 – –
Yes 34 (22.8) 77 (57.9) 4.65 2.78–7.78 <0.001 4.47 2.60–7.67 <0.001
% time on med, first
3 monthsf,g
65.9 (38.2) 66.8 (38.5) 1.00 0.99–1.01 0.844 1.00 0.99–1.01
Clinical
Mode of onseth
Acute 55 (39.8) 67 (51.9) 1.00 – – 1.00 – –
Insidious 83 (60.1) 62 (48.1) 0.61 0.38–1.00 0.048 0.63 0.38–1.05 0.074
DUPh
Short 70 (44.3) 82 (59.4) 1.00 – – 1.00 – –
Long 88 (55.7) 56 (40.6) 0.54 0.34–0.86 0.010 0.54 0.33–0.87 0.012
(Continued )
4 Paola Dazzan et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291719001399
Downloaded from https://www.cambridge.org/core. University of Nottingham, on 05 Aug 2019 at 10:01:25, subject to the Cambridge Core terms of use, available at
Similarly, at follow up only 22.8% (66) had been in paid work.
Most individuals were single throughout follow-up (218, 71.9%)
and at follow-up (205, 67.7%).
Predictors of symptom and functional recovery at 10 years
As noted, we examined the effects of four blocks of factors on
symptom (Table 2) and functional (Table 4) recovery at
10-years: demographic; social; clinical; and early symptom course
(remission at 12-weeks). Effects are shown before and after adjust-
ment for age, gender, study centre, and ethnicity. We additionally
performed these analyses only including the subset of patients
with a diagnosis of schizophrenia (See Supplementary Table).
Predictors of symptom recovery at 10 years
Early symptom course (remission at 12-weeks) strongly predicted
recovery (adj OR 4.47; CI 2.60–7.67). Other variables associated
with recovery (at p < 0.05) were a diagnosis of mania with psych-
osis (adj OR 3.22; CI 1.54–6.73) or of depression with psychosis
(adj OR 1.98; CI 1.00–3.95); and on the dimension scales, a
high symptom score on mania (adj OR 1.14; CI 1.03–1.25) or a
low symptom score on reality distortion (adj OR 0.91; CI 0.83–
1.00). Recovery was less likely ( p⩽ 0.05) among those with
high scores for social disadvantage (score = 3, adj OR 0.40; CI
0.18–0.87; score = 4, adj OR 0.29; CI 0.13–0.67) and non-white
British ethnicity (adj OR 0.43; CI 0.25–0.76) (Table 2).
When we further adjusted for all other variables retained in
our models (as detailed above), strong associations with symptom
recovery at 10 years (n = 213) remained for early symptom course
(remission at 12-weeks) (adj OR 3.33; CI 1.72–6.43), a diagnosis
of psychotic depression (adj OR 2.68; CI 1.02–7.05), and non-
white British ethnicity (adj OR 0.44; CI 0.21–0.91) (Table 3).
Our final model explained around 15% of the variance in
symptom recovery and correctly predicted 61.0% with symptom
recovery.
Predictors of functional recovery at 10 years
Early symptom course (remission at 12-weeks) strongly predicted
functional recovery (i.e. GAF score >60) (adj OR 4.43;
CI 2.46–7.98) (Table 4). The following also strongly predicted
functional recovery (at p⩽ 0.05): study centre (i.e. Nottingham
v. south-east London) (OR 1.88; CI 1.02–3.48); being female
(adj OR 2.19; CI 1.30–3.68); having a diagnosis of mania with
psychosis (adj OR 11.28; CI 4.40–28.92) or depression with
psychosis (adj OR 2.64; CI 1.20–5.85); high mania symptoms
scores (adj OR 1.26; CI 1.12–1.41); and low negative symptom
scores (adj OR 0.78; CI 0.66–0.92).
Functional recovery was less likely among those of non-white
British ethnicity (adj OR 0.50; CI 0.28–0.89); those with no edu-
cational qualifications (adj OR 0.40; CI 0.16–0.99); those with
insidious mode of onset (adj OR 0.41; CI 0.23–0.73); and those
with longer DUP (adj OR 0.41; CI 0.24–0.71) (Table 4). There
was a strong association between recovery and social disadvan-
tage, such that with each additional disadvantage, there was a pro-
gressively lower likelihood of recovery (score = 2, OR 0.35; CI
0.15–0.82; score = 3, OR 0.22; CI 0.09–0.52; and score = 4, OR
0.18; CI 0.07–0.44).
When we further adjusted for all other variables retained in
our models (as detailed above), strong associations with func-
tional recovery at 10 years (n = 213) remained for early symptom
course (remission at 12-weeks) (adj OR 2.75; CI 1.23–6.11), study
centre (i.e. Nottingham v. south-east London) (adj OR 3.23; CI
1.25–8.30), and a diagnosis of mania with psychosis (adj OR
8.17; CI 1.61–41.42) (Table 5). Our final model explained around
32% of the variance in functional recovery and correctly predicted
73.6% with functional recovery.
Table 2. (Continued.)
Not recovered (N = 163) N
(%) or mean (S.D.)
Recovered (N = 140)
N (%) or mean (S.D.)
Unadj.
OR 95% CI p
Adj. OR
(1)a 95% CI p
Diagnosis
Non-affective 132 (81.0) 87 (62.1) 1.00 – – 1.00 – –
Mania 13 (8.0) 28 (20.0) 3.27 1.60–6.66 0.001 3.22 1.54–6.73 0.002
Depression 18 (11.0) 25 (17.9) 2.11 1.09–4.09 0.028 1.98 1.00–3.95 0.052
Dimensionsi
Reality distortion 4.0 (2.9) 3.3 (2.6) 0.91 0.83–0.99 0.031 0.91 0.83–1.00 0.052
Negative 1.3 (1.9) 1.2 (1.9) 0.97 0.86–1.10 0.645 0.97 0.85–1.10 0.646
Disorganised 0.6 (0.7) 0.7 (0.9) 1.20 0.91–1.58 0.207 1.24 0.92–1.65 0.152
Mania 1.2 (2.2) 2.0 (3.1) 1.12 1.02–1.23 0.014 1.14 1.03–1.25 0.010
Depression 1.2 (1.8) 1.4 (1.9) 1.07 0.94–1.22 0.286 1.02 0.89–1.17 0.802
Symptom severityi 8.3 (4.8) 8.7 (5.0) 1.02 0.97–1.07 0.546 1.01 0.96–1.07 0.607
aAdjusted for, as appropriate, centre, sex, age (as continuous variable), and ethnicity
bMissing, 58.
cMissing, 75.
dMissing, 8.
eMissing, 21.
fMissing, 75.
gNote, no variable for percentage of time on medication during first year following contact was associated with recovery.
hMissing, 36.
iMissing, 7.
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Discussion
This is the first long-term, epidemiological, naturalistic follow-up
that has investigated the specific role of early remission and other
predictors of outcome across multiple domains in a cohort of
individuals following their first episode of psychosis. Our main
finding is that symptom remission at 12-weeks is a strong pre-
dictor of both symptom and functional recovery at 10-years.
Furthermore, we found that diagnosis at first onset is a strong pre-
dictor of recovery: depressive psychosis was predictive of good
symptom recovery and manic psychosis was highly predictive of
good functional recovery. Finally, being from the Nottingham
study centre was predictive of good functional recovery. Overall,
our final models explained more of the variance in functional
than symptom outcomes, although for both the percentage
explained was relatively low. Clearly, other unmeasured factors
also contribute to variations in recovery in psychosis.
This study has a number of strengths. It used an incidence
cohort of first episode psychosis patients who presented to any
psychiatric service. This reduced the chances of only including
patients with a particularly illness type, as is often the case for
in-patient populations or those drawn only from early interven-
tion services. The study naturalistic approach makes this sample
as unbiased as possible. Finally, the study is unique in having
evaluated a broad range of predictors across multiple domains
over time, allowing the description of the heterogeneous course
trajectories of psychosis. A major strength is the reporting of
recovery across a range of domains, which has yielded evidence
that predictors of symptom and functional recovery differ and
are somewhat independent of each other.
Some limitations should be acknowledged. As with all longitu-
dinal evaluations, we cannot exclude the potential for selection
and information bias arising from, respectively, loss to follow-up
and missing or inaccurate data. However, we were able to evaluate
the symptom and functional status of over 90% of the cohort. We
found no strong evidence of systematic bias when we compared
those with some information available with those without
(Morgan et al., 2014), suggesting that attrition is unlikely to
have affected findings. The potential for information bias should
also be considered. We made use of all possible sources of infor-
mation, and clinical ratings were made by consensus. To limit the
potential variability in the extent and quality of information avail-
able, we only made ratings of the presence or absence of symptoms
on the basis of clear and definite information. Also, we only con-
sidered lifetime substance use and did not separately consider pat-
terns of use and abstinence following FEP. Finally, completeness of
information was inevitably less for those not re-interviewed.
However, we found that symptom course and outcome were better
Table 3. Symptomatic Recovery at 10 years, adjusted model (number included in analyses = 213)
Adj. ORa 95% CI p Adj. ORb,c,d 95% CI p
Demographic
Ethnicity
White British 1.00 – – 1.00 – –
Other 0.43 0.22–0.85 0.015 0.44 0.21–0.91 0.027
Social
Index of social disadvantage
0, 1 1.00 – – 1.00 – –
2 0.63 0.26–1.49 0.289 0.79 0.31–2.03 0.624
3 0.54 0.24–1.23 0.144 0.70 0.28–1.74 0.444
4 0.29 0.12–0.69 0.006 0.46 0.18–1.18 0.107
Early clinical course
Remission at 12 weeks
No 1.00 – – 1.00 – –
Yes 3.92 2.13–7.21 <0.001 3.33 1.72–6.43 <0.001
Clinical
Diagnosis
Non-affective 1.00 – – 1.00 – –
Mania 4.09 1.71–9.78 0.002 1.74 0.48–6.27 0.395
Depression 2.84 1.17–6.89 0.021 2.68 1.02–7.05 0.045
Dimensions
Reality distortion 0.89 0.80–0.98 0.022 0.94 0.84–1.05 0.289
Mania 1.11 1.00–1.23 0.047 1.03 0.89–1.20 0.704
aAdjusted for centre, sex, age (as continuous variable), and ethnicity
bAdjusted for centre, sex, age (as continuous variable), and ethnicity, and all other variables in table
cPseudo r2 0.15 (i.e. approximately 15% of variance explained by variables in model)
dPercentage with symptom recovery correctly predicted, 61.0%
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Table 4. Functional Recovery (i.e. GAF-D⩾ 60) at 10 years (unless specified, number included in analyses = 286)
Not recovered
(N = 169) N (%)
or mean (S.D.)
Recovered (N = 117)
N (%) or
mean (S.D.) Unadj.OR 95% CI p Adj.OR (1)a 95% CI p
Demographic
Study Centre
London 122 (72.2) 61 (52.1) 1.00 – – 1.00 – –
Nottingham 47 (27.8) 56 (47.9) 2.38 1.45–3.91 0.001 1.88 1.02–3.48 0.043
Sex
Men 105 (62.1) 53 (45.3) 1.00 – – 1.00 – –
Women 64 (37.9) 64 (54.7) 1.98 1.23–3.20 0.005 2.19 1.30–3.68 0.003
Age
16–29 93 (55.0) 58 (49.6) 1.00 – – 1.00 – –
30–64 76 (45.0) 59 (50.4) 1.24 0.78–2.00 0.364 1.29 0.77–2.16 0.325
Ethnicity
White British 50 (29.6) 61 (52.1) 1.00 – – 1.00 – –
Other 119 (70.4) 56 (47.9) 0.39 0.24–0.63 <0.001 0.50 0.28–0.89 0.018
Social
Index of social disadvantageb
0, 1 16 (11.9) 38 (38.0) 1.00 – – 1.00 – –
2 34 (25.4) 25 (25.0) 0.31 0.14–0.68 0.003 0.35 0.15–0.82 0.015
3 43 (32.1) 21 (21.0) 0.21 0.09–0.45 <0.001 0.22 0.09–0.52 0.001
4 41 (30.6) 16 (16.0) 0.16 0.07–0.37 <0.001 0.18 0.07–0.44 <0.001
Loss, separation from parentc
None 58 (45.7) 53 (55.8) 1.00 – – 1.00 – –
Loss (parent died) 12 (9.5) 8 (8.4) 0.73 0.28–1.92 0.524 0.52 0.18–1.54 0.239
Separation from
parent
57 (44.9) 34 (35.8) 0.65 0.37–1.15 0.139 0.73 0.39–1.38 0.336
Educationd
University 12 (7.5) 20 (17.2) 1.00 – – 1.00 – –
Further 49 (30.4) 30 (25.9) 0.37 0.16–0.86 0.021 0.53 0.22–1.31 0.171
GCSE 39 (24.2) 35 (30.2) 0.54 0.23–1.26 0.153 0.85 0.34–2.13 0.726
No qualifications 61 (37.9) 31 (26.7) 0.30 0.13–0.70 0.005 0.40 0.16–0.99 0.047
Early symptom course
Remission at 12 weekse
No 118 (79.2) 48 (44.0) 1.00 – – 1.00 – –
Yes 31 (20.8) 61 (56.0) 4.84 2.80–8.36 <0.001 4.43 2.46–7.98 <0.001
% time on med, first
3 monthsf,g
65.5 (39.4) 70.1 (37.1) 1.00 1.00–1.01 0.363 1.00 0.99–1.01 0.884
Clinical
Mode of onseth
Acute 51 (35.2) 58 (54.7) 1.00 – – 1.00 – –
Insidious 94 (64.8) 48 (45.3) 0.45 0.27–0.75 0.002 0.41 0.23–0.73 0.021
DUPh
Short 68 (42.0) 71 (61.2) 1.00 – – 1.00 – –
Long 94 (58.0) 45 (38.8) 0.46 0.28–0.75 0.002 0.41 0.24–0.71 0.001
(Continued )
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in the Nottingham sample, while, at the same time, cases in
Nottingham were less likely to be re-interviewed.
This is the first time that a role for early symptom remission
(defined with an operationalized set of criteria) has been estab-
lished as important in the long-term outcome of any psychosis.
This finding advances evidence from shorter longitudinal studies
that early symptom remission is associated with better symptom-
atic outcome (Emsley et al., 2006; Verma et al., 2012). It adds to
existing evidence that a shorter proportion of time spent experi-
encing symptoms in the first years of illness (Harrison et al.,
2001) is associated with better long-term outcome, and import-
antly, it demonstrates that this applies to both symptom and func-
tional domains.
This crucial role for early remission could be explained in mul-
tiple ways. These first 12 weeks may be the time required to
receive at least one adequate trial of pharmacological treatment.
While it is theoretically possible that those individuals who did
not achieve early remission were those who had received no or
ineffective treatment, our data suggest this was not the case.
There were no differences in exposure to antipsychotics between
individuals who did and did not remit at 12-weeks. It is also pos-
sible that these early responders represent a subgroup more likely
to respond to treatment. This is consistent with emerging evi-
dence that between 10 and 20% of first episode patients show
rapid response to the first antipsychotic received (Agid et al.,
2013). In our study, these individuals follow a more benign illness
trajectory. They may warrant a less assertive management
approach after the resolution of the first episode. Conversely,
identifying non-responders early in treatment could enable clini-
cians to consider alternative treatment options in order to find the
earliest possible effective treatment (Kinon et al., 2010).
Our data support early management in first episode psychosis,
which aims not only to reduce DUP, but also to promptly reduce
symptom severity, to minimize the time spent with psychotic
symptoms. In our sample, DUP was not a predictor of poor
symptom recovery, but rather a predictor of poor functional
recovery at 10-years. Our interpretation of this finding is that
once patients receive antipsychotic treatment, their ability to
respond is the key predictor of future symptom recovery,
independently of DUP. In turn, a longer DUP may affect their
ability to function in social and occupational spheres, and
where these deficits are engrained over time, they persist even
despite symptomatic improvement. Therefore, while antipsychotic
treatment is an important part of early first episode psychosis
management, it remains only one aspect of the holistic care that
can be provided, which would include also non-pharmacological
interventions such as for example psychoeducation and family
work.
Interestingly, one-third of patients who initially remitted did
not recover in the long-term. This heterogeneity of illness course
may reflect the interplay between external factors and the patho-
physiology of the disorder, which over time generates multiple
possible trajectories. For example, intervening life events, stress,
substance use, ongoing symptoms, family support, vocational
opportunities, compliance with pharmacological and other treat-
ments may independently contribute to shaping illness course
after the initial period (Racenstein et al., 2002; Petersen et al.,
2005; Miller, 2008; Jordan et al., 2014; Colizzi et al., 2016;
Weibell et al., 2017).
Another important predictor of recovery at 10-years was a diag-
nosis of depressive or manic psychosis. To our knowledge, this is
the first time that differences in outcome have been investigated
for affective psychosis diagnostic subtypes. Depressive psychosis
predicted better symptom recovery, while mania strongly predicted
better functional recovery. Affective disorders, in general, have
been reported to be predictive of a better outcome in longitudinal
studies of duration 15–25 years (Marneros et al., 1990; Bottlender
et al., 2010; Henry et al., 2010). Our findings align with long-term
Table 4. (Continued.)
Not recovered
(N = 169) N (%)
or mean (S.D.)
Recovered (N = 117)
N (%) or
mean (S.D.) Unadj.OR 95% CI p Adj.OR (1)a 95% CI p
Diagnosis
Non-affective 145 (85.8) 63 (53.9) 1.00 – – 1.00 – –
Mania 7 (4.1) 33 (28.2) 10.85 4.56–25.84 <0.001 11.28 4.40–28.92 <0.001
Depression 17 (10.1) 21 (17.9) 2.84 1.41–5.75 0.004 2.64 1.20–5.85 0.016
Dimensionsi
Reality distortion 3.9 (3.0) 3.5 (2.5) 0.95 0.87–1.03 0.225 0.99 0.90–1.09 0.864
Negative 1.5 (2.2) 0.9 (1.4) 0.83 0.72–0.96 0.011 0.78 0.66–0.92 0.003
Disorganised 0.7 (0.9) 0.7 (0.9) 1.06 0.81–1.38 0.686 1.04 0.78–1.40 0.775
Mania 1.0 (2.0) 2.5 (3.3) 1.25 1.12–1.39 <0.001 1.26 1.12–1.41 <0.001
Depression 1.2 (1.8) 1.3 (1.8) 1.04 0.91–1.20 0.532 1.02 0.88–1.19 0.757
Symptom severityi 8.3 (4.5) 8.9 (4.9) 1.03 0.98–1.09 0.262 1.04 0.98–1.10 0.188
aAdjusted for, as appropriate, centre, sex, age (as continuous variable), and ethnicity.
bMissing, 52.
cMissing, 64.
dMissing, 9.
eMissing, 28.
fMissing, 58.
gNote, no variable for percentage of time on medication during first year following contact was associated with recovery.
hMissing, 35.
iMissing, 22.
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follow-ups of major depressive disorder (psychotic and non-
psychotic), suggesting that psychosocial disability is associated
with severity of depressive/bipolar 1 symptoms (Judd et al.,
2005). In our study, those patients with a manic presentation
were symptomatic for a shorter period than those with
schizophrenia, and so were more likely to achieve 12-week remis-
sion. However, manic psychosis was an additional highly inde-
pendent predictor of functional recovery. Good functional
recovery was also predicted by being from the Nottingham study
centre. There was evidence that functional outcomes were better,
Table 5. Functional Recovery at 10 years, adjusted model (number included in analyses = 197)
Adj. ORa 95% CI p Adj. ORb,c,d 95% CI p
Demographic
Centre
London 1.00 – – 1.00 – –
Nottingham 3.09 1.42–6.71 0.004 3.23 1.25–8.30 0.015
Sex
Men 1.00 – – 1.00 – –
Women 2.65 1.42–4.94 0.002 1.81 0.85–3.88 0.126
Ethnicity
White British 1.00 – – 1.00 – –
Other 0.56 0.28–1.14 0.110 0.52 0.22–1.25 0.143
Education
University 1.00 – – 1.00 – –
Further 0.29 0.09–0.95 0.040 0.36 0.87–1.49 0.158
GCSE 0.53 0.16–1.72 0.292 1.44 0.35–5.88 0.613
No qualifications 0.20 0.06–0.64 0.007 0.47 0.12–1.90 0.291
Social
Index of social disadvantage
0, 1 1.00 – – 1.00 – –
2 0.37 0.15–0.94 0.036 0.53 0.18–1.56 0.248
3 0.28 0.11–0.70 0.007 0.38 0.12–1.15 0.086
4 0.19 0.07–0.48 0.001 0.38 0.12–1.21 0.101
Early symptom course
Remission at 12 weeks
No 1.00 – – 1.00 – –
Yes 4.04 2.10–8.00 <0.001 2.75 1.23–6.11 0.013
Clinical
DUP
Short 1.00 – – 1.00 – –
Long 0.35 0.18–0.66 0.001 0.52 0.24–1.13 0.098
Diagnosis
Non-affective 1.00 – – 1.00 – –
Mania 14.39 4.50–46.02 <0.001 8.17 1.61–41.42 0.011
Depression 2.76 1.04–7.31 0.042 2.83 0.88–9.07 0.080
Dimensions
Negative 0.87 0.73–1.05 0.161 0.86 0.69–1.09 0.213
Mania 1.20 1.07–1.35 0.002 1.00 0.84–1.19 0.988
Note: Mode of onset and DUP are strongly associated; therefore, only one (DUP) was included in final model.
aAdjusted for centre, sex, age (as continuous variable), and ethnicity.
bAdjusted for centre, sex, age (as continuous variable), and ethnicity, and all other variables in table.
cPseudo r2 0.32 (i.e., approximately 32% of variance explained by variables in model).
dPercentage with functional recovery correctly predicted, 73.6%.
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on average, for patients in Nottingham. While we do not know the
reasons for this, it is tantalising to speculate that the factors related
to urbanicity that increase risk of psychosis onset also impact on its
outcome. Finally, since patients with schizophrenia are those more
likely to be considered for long term maintenance antipsychotic
treatment, we repeated the analyses including only participants
with this diagnosis. We find that even considering only this
group, all findings are in the same direction as the main findings,
though inevitably with some loss of power likely due to the smaller
sample sizes (See online Supplementary Table S1). These add-
itional analyses confirmed that our main finding that early remis-
sion is the best predictor of recovery stands.
While other demographic, clinical, and social factors were con-
sidered, their predictive power in the regression models of 10-year
recovery was modest. The only notable predictor of symptom
recovery, in addition to early remission and depressive psychosis
diagnosis, was White British ethnicity. This is consistent with our
previous findings in this sample, that black Caribbean individuals
experience worse clinical, social, and service use outcomes, and
black African individuals worse social and service use outcomes
(Morgan et al., 2017). There is growing evidence that substance
use is associated with poorer outcomes following FEP (Lambert
et al., 2005; Petersen et al., 2005), but it did not independently
predict outcome in our sample, possibly because of the method
we used to evaluate use. Ideally, substance use throughout
follow-up would be assessed by serial assessments verified by
toxicology. However, this may also be due to the fact that we
included individuals presenting with FEP throughout adulthood
(16–65 years), in contrast to other studies that included younger
individuals in whom substance use is more prevalent [e.g.
(15–29 years) (Lambert et al., 2005); (16–40 years) (Petersen
et al., 2005)].
In conclusion, remission at 12-weeks should be used to inform
clinical management following first episode psychosis. It may
represent a useful means of stratifying patients into treatment pro-
tocols reflecting likely subsequent course. While the diagnosis
may also have a predictive role, with depressive and manic presen-
tations being predictive of long-term clinical and functional
recovery respectively, our data suggest that prediction of long-
term outcome from the first episode of any psychosis remains
extremely challenging.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291719001399.
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